Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 6
2004 2
2005 2
2006 3
2007 2
2008 1
2009 1
2010 3
2011 4
2012 8
2013 5
2014 4
2015 8
2016 7
2017 20
2018 22
2019 27
2020 23
2021 25
2022 30
2023 26
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yapingwu (1 results)?
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, Patel AA, Cheng AC, Watters AL, Bifulco C, Morris G, Rushforth L, Nemeth S, Urba WJ, Gough M, Bell RB. Leidner R, et al. Among authors: wu y. J Immunother Cancer. 2021 May;9(5):e002485. doi: 10.1136/jitc-2021-002485. J Immunother Cancer. 2021. PMID: 33963014 Free PMC article. Clinical Trial.
Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC.
Yao Y, Wang Y, Chen L, Tian Z, Yang G, Wang R, Wang C, Wu Q, Wu Y, Gao J, Kang X, Duan S, Zhang Z, Sun S. Yao Y, et al. Among authors: wu y. Signal Transduct Target Ther. 2022 Mar 8;7(1):73. doi: 10.1038/s41392-022-00908-0. Signal Transduct Target Ther. 2022. PMID: 35260570 Free PMC article. Clinical Trial.
Predictive Markers Require Thorough Analytic Validation.
Troxell ML, Fulton RS, Swanson PE, Bellizzi AM, Fitzgibbons PL, Ambaye AB, Haas TS, Goldsmith JD, Loykasek PA, Miller DV, O'Malley D, Qiu J, Salama ME, Schaberg KB, Schwartz RA, Shia J, Summers TA Jr, Wu Y. Troxell ML, et al. Among authors: wu y. Arch Pathol Lab Med. 2019 Aug;143(8):907-909. doi: 10.5858/arpa.2019-0112-LE. Arch Pathol Lab Med. 2019. PMID: 31339757 Free article. No abstract available.
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
Yamazaki T, Gunderson AJ, Gilchrist M, Whiteford M, Kiely MX, Hayman A, O'Brien D, Ahmad R, Manchio JV, Fox N, McCarty K, Phillips M, Brosnan E, Vaccaro G, Li R, Simon M, Bernstein E, McCormick M, Yamasaki L, Wu Y, Drokin A, Carnahan T, To Y, Redmond WL, Lee B, Louie J, Hansen E, Solhjem MC, Cramer J, Urba WJ, Gough MJ, Crittenden MR, Young KH. Yamazaki T, et al. Among authors: wu y. Lancet Oncol. 2022 Sep;23(9):1189-1200. doi: 10.1016/S1470-2045(22)00446-6. Epub 2022 Aug 8. Lancet Oncol. 2022. PMID: 35952709 Clinical Trial.
231 results